

Reply to comment

Thank for notification for revision. Revision is done according to all comments. Revision is in red/tracked. Point by point response is given below

**Scientific Quality:** Grade B (Very good)

**Language Quality:** Grade A (Priority publishing)

**Conclusion:** Accept (General priority)

This reviewer does not have any comments to the authors.

thank for the note. there is no specific comment

**Scientific Quality:** Grade C (Good)

**Language Quality:** Grade B (Minor language polishing)

**Conclusion:** Accept (General priority)

I agree with your ideas. According to a cited case report, IgG4 related cholangitis and pancreatitis occurred after the administration of nivolumab. However, even pathologic findings cannot confirm the involvement of IgG4-associated cholangitis and pancreatitis and nivolumab; nivolumab may have triggered IgG4 related cholangitis and pancreatitis on the basis of time course. Therefore, a definitive diagnosis requires exclusion of all alternative options for comorbidities.

Reply: thank for the note. The mentioned discussion is added.

Also, English editing is done.